Viridian (VRDN) | Stock Overview & Key Data
Viridian Performance Comparison
Stock Range
Today's Range
Low: $17.99
High: $19.60
on August 22, 2025
52 Week Range
Low: $9.90
High: $27.20
on April 9, 2025
on November 12, 2024
All-Time High: $2,247.75 on June 16, 2014
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.4B
EPS
-3.57
P/E Ratio (TTM)
-5.91
Forward P/E
-4.19
P/B Ratio
4.38
PEG Ratio
3.01
Div. Yield
N/A
ROE
-65.88%
Beta
0.482
Debt to Equity
4.48
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-142,356.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-39.77%
Return on Equity (TTM)
-65.88%
EBITDA
$-371.1M
Net Income (TTM)
$-275.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.00
Quarterly Revenue Growth (YoY)
4.20%
Quarterly Earnings Growth (YoY)
4.17%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Viridian VRDN | 1.43B Small-cap | -2.28% | 7.33% | 31.92% | 10.76% | -8.81% | 19.73% | -25.10% | 27.89% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| Cg Oncology CGON | 1.99B Small-cap | 0.08% | -3.42% | -0.92% | -6.71% | -10.32% | -29.82% | -25.83% | -25.83% |
| Adaptive ADPT | 1.99B Small-cap | -2.24% | 22.50% | 38.94% | 52.72% | 104.04% | 159.88% | 20.52% | -69.05% |
| Vericel VCEL | 1.80B Small-cap | -0.92% | -0.06% | -13.71% | -31.85% | -35.69% | -28.10% | 30.92% | 116.49% |
Ownership & Short Interest
Insider Ownership
0.16%
Institutional Ownership
118.71%
Shares Short
12M
Short Ratio
17.20
Short % of Shares Outstanding
14.94%
Average 10-Day Volume
791K
Average 90-Day Volume
708K
Viridian Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Viridian would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is VRDN's 52-week high and low?
- In the last 52 weeks, Viridian reached a high of $27.20 (on November 12, 2024) and a low of $9.90 (on April 9, 2025).
- What is the market cap and P/E ratio for VRDN?
- Curious about Viridian's size and valuation? Its market capitalization stands at 1.43B. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.91, and the forward P/E (looking ahead) is -4.19.
- Does VRDN pay dividends? If so, what's the yield?
- As for dividends, Viridian isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Viridian's main competitors or similar companies to consider before investing?
When looking at Viridian, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% Cg Oncology
CGON1.99B Healthcare Biotechnology -29.82% -25.83% Adaptive
ADPT1.99B Healthcare Biotechnology 159.88% 20.52% Vericel
VCEL1.80B Healthcare Biotechnology -28.10% 30.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Viridian Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Viridian's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -65.88%, the Debt to Equity ratio from the most recent quarter is 4.48, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for VRDN?
- Looking at Viridian's growth, its revenue over the trailing twelve months (TTM) was $305K. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.20%, and quarterly earnings saw a YoY growth of 4.17%.
- How much of VRDN stock is held by insiders and institutions?
- Wondering who owns Viridian stock? Company insiders (like executives and directors) hold about 0.16% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 118.71%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.